Anthera Pharmaceuticals (ANTH) Shares Up 6.3%

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s share price shot up 6.3% on Thursday . The stock traded as high as $0.36 and last traded at $0.34. 1,552,818 shares were traded during trading, a decline of 46% from the average session volume of 2,863,548 shares. The stock had previously closed at $0.32.

Several research firms recently weighed in on ANTH. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Piper Jaffray lowered shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a report on Monday, March 12th. HC Wainwright reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Roth Capital began coverage on shares of Anthera Pharmaceuticals in a report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Jefferies Group reiterated a “hold” rating and issued a $0.50 price objective on shares of Anthera Pharmaceuticals in a report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Anthera Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $4.06.

How to Become a New Pot Stock Millionaire

The firm has a market capitalization of $8.05, a P/E ratio of -0.08 and a beta of 2.76.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. sell-side analysts expect that Anthera Pharmaceuticals Inc will post -1.68 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of ANTH. Armistice Capital LLC acquired a new position in Anthera Pharmaceuticals in the 4th quarter worth $1,269,000. BVF Inc. IL lifted its holdings in Anthera Pharmaceuticals by 20.9% in the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 209,896 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Anthera Pharmaceuticals in the 4th quarter valued at about $399,000. Hedge funds and other institutional investors own 16.65% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3338293/anthera-pharmaceuticals-anth-shares-up-6-3.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sysco  and Domino’s Pizza  Critical Comparison
Sysco and Domino’s Pizza Critical Comparison
Universal Display  and AVX  Head to Head Comparison
Universal Display and AVX Head to Head Comparison
Head-To-Head Analysis: Torchmark  vs. Its Competitors
Head-To-Head Analysis: Torchmark vs. Its Competitors
Zacks: Analysts Expect Applied Optoelectronics  to Post $0.33 EPS
Zacks: Analysts Expect Applied Optoelectronics to Post $0.33 EPS
-$0.14 EPS Expected for Achillion Pharmaceuticals  This Quarter
-$0.14 EPS Expected for Achillion Pharmaceuticals This Quarter
$0.95 EPS Expected for Aaron’s, Inc.  This Quarter
$0.95 EPS Expected for Aaron’s, Inc. This Quarter


© 2006-2018 Ticker Report. Google+.